Pietro Querzani
A5020652575- Migraine and Headache Studies
- Acute Ischemic Stroke Management
- Trigeminal Neuralgia and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Psychosomatic Disorders and Their Treatments
- Peripheral Neuropathies and Disorders
- Cerebrovascular and Carotid Artery Diseases
- Long-Term Effects of COVID-19
- Ophthalmology and Eye Disorders
- Neurological Disorders and Treatments
- Neurosurgical Procedures and Complications
- COVID-19 and healthcare impacts
- Multiple Sclerosis Research Studies
- Peripheral Artery Disease Management
- Systemic Lupus Erythematosus Research
- Cerebral Venous Sinus Thrombosis
- Retinal and Optic Conditions
- Genetic Neurodegenerative Diseases
- Neurological and metabolic disorders
- Autoimmune Neurological Disorders and Treatments
- Intracerebral and Subarachnoid Hemorrhage Research
- Healthcare Systems and Technology
- Nicotinic Acetylcholine Receptors Study
- Emergency and Acute Care Studies
- Spatial Neglect and Hemispheric Dysfunction
Ospedale "Santa Maria delle Croci" di Ravenna
2004-2024
University of Bologna
2020
Azienda Unità Sanitaria Locale Della Romagna
2018
Ospedale G.B. Morgagni - L.Pierantoni
2004
To verify the long-term (24-week) efficacy, safety, and tolerability of fremanezumab in real-life patients with high-frequency episodic migraine (HFEM: ≥ 8 days/month) or chronic (CM: 15 days/month), multiple preventive treatment failures.This is a prospective, cohort, study at 28 headache centers on consecutive affected by HFEM CM failures who were prescribed subcutaneous (225 mg monthly/675 quarterly) for 24 weeks. Primary endpoint was change monthly days (MMDs) (MHDs) weeks 21-24 compared...
Randomized controlled trials (RCTs) proved that short-term (21-90 days) dual antiplatelet therapy (DAPT) reduces the risk of early ischemic recurrences after a noncardioembolic minor stroke or high-risk transient attack (TIA) without substantially increasing hemorrhagic risk. We aimed at understanding whether and how real-world use DAPT differs from RCTs.READAPT (Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke TIA) is prospective cohort study...
Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine < 2 medication clusters a randomized controlled trial (RCT). We aimed assess real-world evidence (RWE), long-term effectiveness, tolerability, safety of people high-frequency episodic (HFEM) or chronic (CM) > 3 failures various comorbidities. A 48-week, prospective, multicenter (n = 26), cohort study assessed fremanezumab's safety, tolerability consecutive adults HFEM CM...
Randomized controlled trials (RCTs) proved the efficacy of short-term dual antiplatelet therapy (DAPT) in secondary prevention minor ischemic stroke or high-risk transient attack (TIA). We aimed at evaluating effectiveness and safety DAPT real-world, where treatment use is broader than RCTs.
Background The optimal treatment for acute minor ischemic stroke is still undefined. and options include dual antiplatelet (DAPT), intravenous thrombolysis (IVT), or their combination. We aimed to investigate benefits risks of combining IVT DAPT versus alone in patients with MIS. Methods Results This a prespecified propensity score‐matched analysis from prospective multicentric real‐world study (READAPT [Real‐Life Study on Short‐Term Dual Antiplatelet Treatment Patients With Ischemic Stroke...
Mechanisms underlying the self/other distinction have been mainly investigated focusing on visual, tactile or proprioceptive cues, whereas very little is known about contribution of acoustical information. Here ability to distinguish between self and others' voice by using a neuropsychological approach. Right (RBD) left brain damaged (LBD) patients healthy controls were submitted discrimination recognition task. Stimuli paired words/pseudowords pronounced participant, familiar unfamiliar...
Background: According to the literature, about one third of patients with brain ischemic symptoms lasting <24 h, which are classified as Transient attacks (TIAs) according traditional “time-based” definition, show presence acute lesions at neuroimaging. Recent evidence has shown that neuroimaging may impact on outcome transient treated dual antiplatelet treatment (DAPT). This uncertainty is even more compelling in recent years short-term DAPT become standard for any non-cardioembolic TIA...
A healthy 53-year-old man developed acute flaccid paraplegia, spinal sensory level, and urinary retention. Examination revealed bilateral pronator drift. MRI demonstrated demyelinating non-enhancing lesions involving corticospinal tracts (CSTs), middle cerebellar peduncles, cord (figure 1). CSF analysis disclosed lymphocytic pleocytosis mildly elevated protein. Euroimmun fixed cell-based assay for serum anti–myelin oligodendrocyte glycoprotein (MOG) anti–aquaporin-4 (AQP4) antibodies showed...
Background and purpose: Clinical trials proved the efficacy of short-term dual antiplatelet therapy (DAPT) in secondary prevention minor ischemic stroke or high-risk transient attack (TIA). In clinical practice, use DAPT is broader than procedures (i.e. loading dose, timely treatment start) are not always followed. We aimed at evaluating effectiveness safety real-world. Methods: READAPT (A REAl-life study on Dual Antiplatelet Patients with Transient attack) ( NCT05476081 ) was an...
Friedreich ataxia is the most common form of hereditary ataxia. Heart involvement in and can include increased left ventricular wall thickness, atrial fibrillation, later stages, a reduction ejection fraction. We present case 45-year-old man with history paroxysmal fibrillation congestive heart failure, hypertension, age ⩾ 75 years, diabetes mellitus, stroke, vascular disease, 65–74 female sex (CHA2DS2-VASc) score only 1 (because reduced fraction) who presented pneumonia was also found to...